A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Authors: Moskowitz, Alison J. ^*, Ghione, Paola, Jacobsen, Eric, Ruan, Jia, Schatz, Jonathan H., Noor, Sarah, Myskowski, Patricia, Vardhana, Santosha, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Perez, Leslie, Ryu, Sunyoung, Santarosa, Alayna, Dowd, Jack, Obadi, Obadi, Pomerantz, Lauren, Yi, Nancy, Sohail, Samia, Galasso, Natasha, Neuman, Rachel, Liotta, Brielle, Blouin, William, Baik, Jeeyeon, Geyer, Mark B., Noy, Ariela, Straus, David, Kumar, Priyadarshini, Dogan, Ahmet, Hollmann, Travis, Drill, Esther, Rademaker, Jurgen, Schoder, Heiko, Inghirami, Giorgio, Weinstock, David M., Horwitz, Steven M.

Source: In Blood 30 December 2021 138(26):2828-2837

Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Authors: Wills, Beatriz, Ganesan, Nivetha ^*, Shah, Gunjan L. ^*, Wong, Phillip ^*, Argyropoulos, Kimon V. ^*, Sen, Filiz ^*, Dogan, Ahmet, Straus, David J., Noy, Ariela, Kumar, Anita, Schoder, Heiko ^*, Michaud, Laure ^*, Palomba, Maria Lia, Falchi, Lorenzo, Lahoud, Oscar B, Hamlin, Paul A., Yahalom, Joachim, Johnson, William T., Zelenetz, Andrew D., Intlekofer, Andrew M., Owens, Colette, Batlevi, Connie Lee, Hamilton, Audrey ^*, Caron, Philip C, Horwitz, Steven M., Galasso, Natasha ^*, Hancock, Helen ^*, Davey, Theresa ^*, Santarosa, Alayna ^*, Perez, Leslie ^*, Capadona, Charisse ^*, Munayirji, Brittney ^*, Matasar, Matthew J., Pongas, Georgios, Casper, Ellie ^*, Salles, Gilles, Moskowitz, Craig H., Vardhana, Santosha, Moskowitz, Alison J.

Source: In Blood 15 November 2022 140 Supplement 1:9286-9288

Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Authors: Shah, Gunjan L., Moskowitz, Alison, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Sohail, Samia, Santarosa, Alayna, Lyons, Jennifer, Ruiz, Josel D., Kumar, Anita, Batlevi, Connie W, Caron, Philip, Hamlin, Paul, Matasar, Matthew J., Rodriguez-Rivera, Ildefonso, Straus, David, von Keudell, Gottfried, Yahalom, Joachim, Dahi, Parastoo B., Lahoud, Oscar B., Scordo, Michael, Perales, Miguel, Sauter, Craig S., Moskowitz, Craig H.

Source: Transplantation and Cellular Therapy. 27(S):S68-S69

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134294540.0x000001&indx=1&recIds=ETOCvdc_100134294540.0x000001

Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma

Authors: Wills, Beatriz, Rahman, Jahan, Ganesan, Nivetha, Shah, Gunjan L., Noy, Ariela, Schoder, Heiko, Yahalom, Joachim, Kumar, Anita, Falchi, Lorenzo, Hamlin, Paul A., Palomba, Maria Lia, Johnson, William, Intlekofer, Andrew M., Caron, Philip, Davey, Theresa, Hancock, Helen, Galasso, Natasha, Munayirji, Brittney, Hui Lin, Ya, Santarosa, Alayna, Casper, Ellie, Pongas, Georgio, Zelenetz, Andrew D., Moskowitz, Craig H., Salles, Gilles, Vardhana, Santosha A, Moskowitz, Alison

Source: In Blood 28 November 2023 142 Supplement 1:1623-1623

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Authors: Moskowitz, Alison J, Shah, Gunjan, Schöder, Heiko, Ganesan, Nivetha, Drill, Esther, Hancock, Helen, Davey, Theresa, Perez, Leslie, Ryu, Sunyoung, Sohail, Samia, Santarosa, Alayna, Galasso, Natasha, Neuman, Rachel, Liotta, Brielle, Blouin, William, Kumar, Anita, Lahoud, Oscar, Batlevi, Connie L, Hamlin, Paul, Straus, David J

Source: Journal of Clinical Oncology; 10/1/2021, Vol. 39 Issue 28, p3109-3117, 9p

71 - Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Authors: Shah, Gunjan L., Moskowitz, Alison, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Sohail, Samia, Santarosa, Alayna, Lyons, Jennifer, Ruiz, Josel D., Kumar, Anita, Batlevi, Connie W, Caron, Philip, Hamlin, Paul, Matasar, Matthew J., Rodriguez-Rivera, Ildefonso, Straus, David, von Keudell, Gottfried, Yahalom, Joachim, Dahi, Parastoo B., Lahoud, Oscar B., Scordo, Michael, Perales, Miguel, Sauter, Craig S., Moskowitz, Craig H.

Source: In Transplantation and Cellular Therapy March 2021 27(3) Supplement:S68-S69

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Authors: Moskowitz, Alison J., Shah, Gunjan ^*, Schöder, Heiko ^*, Ganesan, Nivetha ^*, Hancock, Helen ^*, Davey, Theresa ^*, Sohail, Samia ^*, Santarosa, Alayna ^*, Pomerantz, Lauren ^*, Jarjies, Christine ^*, Galasso, Natasha ^*, Neuman, Rachel ^*, Kumar, Anita, Lahoud, Oscar B, Batlevi, Connie Lee, Hamlin, Paul A., Straus, David J., Rodriguez-Rivera, Ildefonso ^*, Owens, Colette, Caron, Philip, Intlekofer, Andrew M., Hamilton, Audrey ^*, Horwitz, Steven M., Falchi, Lorenzo, Joffe, Erel, Palomba, Maria Lia, Noy, Ariela, Matasar, Matthew J, Pongas, Georgios, Vardhana, Santosha ^*, von Keudell, Gottfried R., Yahalom, Joachim, Zelenetz, Andrew D, Moskowitz, Craig H.

Source: In Blood 5 November 2020 136 Supplement 1:17-18

T099: High efficacy and durability of second‐line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma.

Authors: Moskowitz, Alison J., Shah, Gunjan, Schöder, Heiko, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Perez, Leslie, Sohail, Samia, Santarosa, Alayna, Capadona, Charisse, Munayirji, Brittney, Kumar, Anita, Lahoud, Oscar, Batlevi, Connie, Hamlin, Paul, Straus, David J., Owens, Colette, Caron, Philip, Intlekofer, Andrew, Hamilton, Audrey

Source: HemaSphere; 2022 Supplement, Vol. 6, p45-46, 2p